1 / 35

Optimizing Therapy Through the Prevention and/or Management of Adverse Events in Multiple Myeloma

Optimizing Therapy Through the Prevention and/or Management of Adverse Events in Multiple Myeloma. Goal Statement. Case #1 . Question . Venous Thromboembolism. Risk Factors for VTE in Patients With Malignancy. VTE Incidence With Thalidomide or Lenalidomide Without Thromboprophylaxis.

tausiq
Download Presentation

Optimizing Therapy Through the Prevention and/or Management of Adverse Events in Multiple Myeloma

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Optimizing Therapy Through the Prevention and/or Management of Adverse Events in Multiple Myeloma

  2. Goal Statement

  3. Case #1

  4. Question

  5. Venous Thromboembolism

  6. Risk Factors for VTE in Patients With Malignancy

  7. VTE Incidence With Thalidomide or Lenalidomide Without Thromboprophylaxis

  8. Guideline Recommendations: Prevention of VTE

  9. Guideline Recommendations: Prevention of VTE (cont)

  10. Case #1 (cont)

  11. Question

  12. Bisphosphonate-Related ONJ

  13. BRONJ Incidence

  14. BRONJ Risk Factors

  15. BRONJ Definition

  16. Prevention of BRONJ

  17. Strategies for Preventing BRONJ

  18. Treatment of Patients With BRONJ

  19. Case #2

  20. Case #2 (cont)

  21. Question

  22. Peripheral Neuropathy

  23. TiPN and BiPN

  24. Carfilzomib: PN

  25. Management of PN

  26. Management of PN: TiPN

  27. Management of PN: BiPN

  28. Question

  29. Myelosuppression

  30. Myelosuppression: Bortezomib

  31. Myelosuppression: Lenalidomide

  32. Myelosuppression: Carfilzomib

  33. Question & Answer Session

More Related